TY - JOUR
T1 - Effects of oral administration of androstenedione on plasma androgens in young women using hormonal contraception
AU - Bassindale, T
AU - Cowan, D A
AU - Dale, S
AU - Hutt, A J
AU - Leeds, A R
AU - Wheeler, M J
AU - Kicman, A T
PY - 2004/12
Y1 - 2004/12
N2 - Androstenedione as a dietary supplement has been targeted at the sporting community, but there are limited data regarding its effects on plasma androgens in young women. A double-blind, cross-over study was undertaken involving 10 women ( 20 - 32 yr) using hormonal contraception. Because contamination of supplements has been reported, an in-house oral formulation was prepared containing purified androstenedione, the control being lactose only. After oral administration of a single dose of androstenedione ( 100 mg), blood was collected frequently up to 8 h and at 24 h. Maximum plasma androgen concentrations observed between volunteers were well above the upper limit of reference ranges for women, being 121 - 346 nmol/liter for androstenedione, 14 - 54 nmol/ liter for testosterone (T), 11 - 32 nmol/liter for 5alpha-dihydrotestosterone, and 23 - 90 nmol/liter for 3alpha-androstanediol glucuronide. The free androgen index and T concentration changed in a similar manner. The mean change in area under the plasma concentration-time curve ( 0 - 24 h), compared with control data were: androstenedione approximately 7-fold, T approximately 16-fold, 5alpha-dihydrotestosterone approximately 9-fold, and 3alpha-androstanediol glucuronide approximately 5-fold; the mean conversion ratio of androstenedione to T was 12.5% ( range 7.8 - 21.6%). Increases in T area under the plasma concentration-time curve were correlated with SHBG concentration (r = 0.80; P = 0.005). Formulation characteristics and SHBG levels appear to be important factors when considering plasma androgen increases after acute androstenedione administration.
AB - Androstenedione as a dietary supplement has been targeted at the sporting community, but there are limited data regarding its effects on plasma androgens in young women. A double-blind, cross-over study was undertaken involving 10 women ( 20 - 32 yr) using hormonal contraception. Because contamination of supplements has been reported, an in-house oral formulation was prepared containing purified androstenedione, the control being lactose only. After oral administration of a single dose of androstenedione ( 100 mg), blood was collected frequently up to 8 h and at 24 h. Maximum plasma androgen concentrations observed between volunteers were well above the upper limit of reference ranges for women, being 121 - 346 nmol/liter for androstenedione, 14 - 54 nmol/ liter for testosterone (T), 11 - 32 nmol/liter for 5alpha-dihydrotestosterone, and 23 - 90 nmol/liter for 3alpha-androstanediol glucuronide. The free androgen index and T concentration changed in a similar manner. The mean change in area under the plasma concentration-time curve ( 0 - 24 h), compared with control data were: androstenedione approximately 7-fold, T approximately 16-fold, 5alpha-dihydrotestosterone approximately 9-fold, and 3alpha-androstanediol glucuronide approximately 5-fold; the mean conversion ratio of androstenedione to T was 12.5% ( range 7.8 - 21.6%). Increases in T area under the plasma concentration-time curve were correlated with SHBG concentration (r = 0.80; P = 0.005). Formulation characteristics and SHBG levels appear to be important factors when considering plasma androgen increases after acute androstenedione administration.
UR - http://www.scopus.com/inward/record.url?scp=10344259094&partnerID=8YFLogxK
U2 - 10.1210/jc.2004-0790
DO - 10.1210/jc.2004-0790
M3 - Article
SN - 1945-7197
VL - 89
SP - 6030
EP - 6038
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 12
ER -
